Literature DB >> 21182227

High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.

Matteo Nicola Dario Di Minno1, Antonella Tufano, Anna Rusolillo, Giovanni Di Minno, Giovanni Tarantino.   

Abstract

AIM: to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with idiopathic venous thromboembolism (VTE).
METHODS: in a case-control study, after excluding subjects with well-consolidated risk factors for VTE, idiopathic VTE was documented in 138 consecutive patients who were referred to our department. Two hundred and seventy-six healthy sex/age/body-mass-index-matched subjects, without any clinical/instrumental evidence of VTE, served as controls. All underwent a clinical/laboratory/ultrasound assessment for the presence of metabolic syndrome and NAFLD.
RESULTS: NAFLD was detected in 112/138 cases (81%) and in 84/276 controls (30%) [risk ratio: 2.7, 95% confidence interval (CI): 2.2-3.2, P < 0.0001]. Metabolic syndrome and smoking habit were more prevalent in patients with idiopathic VTE. The high prevalence of NAFLD in VTE was also confirmed after adjustment for inherited thrombophilia. NAFLD was clearly predicted by VTE (odds ratio: 1.8, 95% CI: 1.2-2.7, P < 0.0001).
CONCLUSION: NAFLD was independently associated with idiopathic VTE.

Entities:  

Mesh:

Year:  2010        PMID: 21182227      PMCID: PMC3012581          DOI: 10.3748/wjg.v16.i48.6119

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

Review 2.  Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.

Authors:  I Juhan-Vague; M C Alessi; P E Morange
Journal:  Ann Med       Date:  2000-12       Impact factor: 4.709

3.  The risk of venous thromboembolism is markedly elevated in patients with diabetes.

Authors:  V Petrauskiene; M Falk; I Waernbaum; M Norberg; J W Eriksson
Journal:  Diabetologia       Date:  2005-03-19       Impact factor: 10.122

4.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

5.  Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  A Festa; R D'Agostino; L Mykkänen; R P Tracy; D J Zaccaro; C N Hales; S M Haffner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

6.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Joseph F Polak; Aaron R Folsom
Journal:  Arch Intern Med       Date:  2002-05-27

7.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

Review 8.  Venous thrombosis: a multicausal disease.

Authors:  F R Rosendaal
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

9.  Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; María Soledad Rosselli; Tomas Fernández Gianotti; Pablo Mallardi; Julio San Martino; Carlos Jose Pirola
Journal:  Atherosclerosis       Date:  2009-10-13       Impact factor: 5.162

10.  Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1.

Authors:  Hongwei Yuan; John Y-J Shyy; Manuela Martins-Green
Journal:  J Hepatol       Date:  2009-05-18       Impact factor: 25.083

View more
  22 in total

Review 1.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

Review 2.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 3.  Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.

Authors:  Alexandra Jichitu; Simona Bungau; Ana Maria Alexandra Stanescu; Cosmin Mihai Vesa; Mirela Marioara Toma; Cristiana Bustea; Stela Iurciuc; Marius Rus; Nicolae Bacalbasa; Camelia Cristina Diaconu
Journal:  Diagnostics (Basel)       Date:  2021-04-12

4.  Elevated hepatic enzymes and incidence of venous thromboembolism: a prospective study.

Authors:  Aaron R Folsom; Pamela L Lutsey; Nicholas S Roetker; Wayne D Rosamond; Mariana Lazo; Susan R Heckbert; Saonli Basu; Mary Cushman; Elizabeth Selvin
Journal:  Ann Epidemiol       Date:  2014-09-08       Impact factor: 3.797

5.  Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery.

Authors:  E Pardina; R Ferrer; J Rossell; D Ricart-Jané; K A Méndez-Lara; J A Baena-Fustegueras; A Lecube; J Julve; J Peinado-Onsurbe
Journal:  Int J Obes (Lond)       Date:  2017-05-10       Impact factor: 5.095

Review 6.  Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Walter Ageno; Paolo Prandoni; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2011-04-02       Impact factor: 3.397

7.  Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.

Authors:  Srinevas K Reddy; Min Zhan; H Richard Alexander; Samer S El-Kamary
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 8.  Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.

Authors:  Matteo Nicola Dario Di Minno; Anna Russolillo; Roberta Lupoli; Pasquale Ambrosino; Alessandro Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

Review 9.  Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations.

Authors:  Alexander J Kovalic; George Cholankeril; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2019-09-03

10.  Effect of type 1 diabetes and type 2 diabetes on the risk of venous thromboembolism.

Authors:  William Hinton; Banne Nemeth; Simon de Lusignan; Ben Field; Michael D Feher; Neil Munro; Lara N Roberts; Roopen Arya; Martin B Whyte
Journal:  Diabet Med       Date:  2020-11-27       Impact factor: 4.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.